Ovid Therapeutics Inc. (OVID)
NASDAQ: OVID · Real-Time Price · USD
1.670
+0.050 (3.09%)
At close: Dec 5, 2025, 4:00 PM EST
1.650
-0.020 (-1.20%)
After-hours: Dec 5, 2025, 7:06 PM EST
Ovid Therapeutics Employees
Ovid Therapeutics had 23 employees as of December 31, 2024. The number of employees decreased by 17 or -42.50% compared to the previous year.
Employees
23
Change (1Y)
-17
Growth (1Y)
-42.50%
Revenue / Employee
$287,391
Profits / Employee
-$1,559,652
Market Cap
118.92M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
OVID News
- 4 days ago - Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer - GlobeNewsWire
- 24 days ago - Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Ovid Therapeutics Inc. - Special Call - Seeking Alpha
- 2 months ago - Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds - GlobeNewsWire
- 2 months ago - Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile - GlobeNewsWire
- 4 months ago - Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results - GlobeNewsWire
- 4 months ago - Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference - GlobeNewsWire
- 5 months ago - Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties - GlobeNewsWire